Tango Biosciences

Tango Biosciences is a private, revenue-generating CRO leveraging its proprietary phage display platform to deliver custom antibodies, peptides, and assay solutions. Its core business model is providing fee-for-service R&D, primarily serving clients in drug discovery and diagnostics. The company is led by experienced phage display experts and has secured non-dilutive funding, including an NIH SBIR grant, to expand its platform into novel areas like molecular glues.

Proprietary phage display platform for discovering peptides, antibodies, and binding molecules. Includes high-diversity libraries, an integrated validation suite (MILKSHAKE/Sundae assays), and the developing Avidimer platform for molecular glue discovery.

Tango competes with other specialty CROs offering phage/display services (e.g., Dyax, Creative Biolabs), large full-service CROs with discovery divisions, and in-house capabilities at large pharma. Its differentiation is based on claimed speed, reliability, and expertise with challenging targets, as well as its novel Avidimer platform under development.